Loxapina [Inn-Spanish] Uses

Did you have any side effects with this medicine?

What is Loxapina [Inn-Spanish]?

Loxapina [Inn-Spanish] is an antipsychotic medication. It affects the actions of chemicals in your brain.

Loxapina [Inn-Spanish] is used to treat agitation related to schizophrenia or bipolar disorder.

Loxapina [Inn-Spanish] inhalation is given only in a hospital or clinic setting where any breathing problems can be quickly treated.

Loxapina [Inn-Spanish] inhalation may also be used for purposes not listed in this medication guide.

Loxapina [Inn-Spanish] indications

infoAn indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.

Loxapina [Inn-Spanish] is a typical antipsychotic indicated for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.

"Psychomotor agitation" is defined in DSM-IV as "excessive motor activity associated with a feeling of inner tension." Patients experiencing agitation often manifest behaviors that interfere with their care (e.g., threatening behaviors, escalating or urgently distressing behavior, self-exhausting behavior), leading clinicians to the use of rapidly absorbed antipsychotic medications to achieve immediate control of the agitation.

The efficacy of Loxapina [Inn-Spanish] was established in one study of acute agitation in patients with schizophrenia and one study of acute agitation in patients with bipolar I disorder.

Limitations of Use:

As part of the Loxapina [Inn-Spanish] REMS Program to mitigate the risk of bronchospasm, Loxapina [Inn-Spanish] must be administered only in an enrolled healthcare facility.

How should I use Loxapina [Inn-Spanish]?

Use Loxapina [Inn-Spanish] powder as directed by your doctor. Check the label on the medicine for exact dosing instructions.

  • Loxapina [Inn-Spanish] powder comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Loxapina [Inn-Spanish] powder refilled.
  • Loxapina [Inn-Spanish] powder is for oral inhalation only. It will be given at your doctor's office, hospital, or clinic. Your health care provider will teach you how to use it. Be sure you understand how to use Loxapina [Inn-Spanish] powder. Follow the procedures you are taught when you use a dose.
  • Your health care provider will check you for breathing problems after you use Loxapina [Inn-Spanish] powder and at least every 15 minutes for at least 1 hour after you use it.
  • You should receive Loxapina [Inn-Spanish] powder only under direct medical supervision by a doctor experienced in the use of Loxapina [Inn-Spanish] powder.
  • If you miss a dose of Loxapina [Inn-Spanish] powder, contact your doctor right away.

Ask your health care provider any questions you may have about how to use Loxapina [Inn-Spanish] powder.

Uses of Loxapina [Inn-Spanish] in details

infoThere are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.

Loxapina [Inn-Spanish] is used in adults to treat agitation due to schizophrenia (psychiatric or mental disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations and withdrawal into the self) and bipolar disorder (cyclical over excitation and depression).

Loxapina [Inn-Spanish] description

An antipsychotic agent used in schizophrenia. [PubChem]

Loxapina [Inn-Spanish] dosage

Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) Capsules USP are administered, usually in divided doses, two to four times a day. Daily dosage (in terms of base equivalents) should be adjusted to the individual patient's needs as assessed by the severity of symptoms and previous history of response to antipsychotic drugs.

Oral Administration

Initial dosage of 10 mg twice daily is recommended, although in severely disturbed patients initial dosage up to a total of 50 mg daily may be desirable. Dosage should then be increased fairly rapidly over the first seven to ten days until there is effective control of symptoms of schizophrenia. The usual therapeutic and maintenance range is 60 mg to 100 mg daily. However, as with other drugs used to treat schizophrenia, some patients respond to lower dosage and others require higher dosage for optimal benefit. Daily dosage higher than 250 mg is not recommended.

Maintenance Therapy

For maintenance therapy, dosage should be reduced to the lowest level compatible with symptom control; many patients have been maintained satisfactorily at dosages in the range of 20 to 60 mg daily.

How supplied

Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) Capsules USP are available in the following strengths:

Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) Succinate 6.8 mg equivalent to 5 mg Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate), black ink, hard shell, opaque, with a white body and cap, printed with Watson 369 on one half and 5 mg on the other, are supplied in bottles of 100.

Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) Succinate 13.6 mg equivalent to 10 mg Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate), black ink, hard shell, opaque, with a white body and yellow cap, printed with Watson 370 on one half and 10 mg on the other, are supplied in bottles of 100.

Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) Succinate 34.0 mg equivalent to 25 mg Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate), black ink, hard shell, opaque, with a white body and green cap, printed with Watson 371 on one half and 25 mg on the other, are supplied in bottles of 100.

Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) Succinate 68.1 mg equivalent to 50 mg Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate), black ink, hard shell, opaque, with a white body and blue cap, printed with Watson 372 on one half and 50 mg on the other, are supplied in bottles of 100.

Store at 20°-25°C (68°-77°F). Dispense in a tight, child-resistant container.

Watson Laboratories, Inc. Corona, CA 92880, USA. Revised: March 2008. FDA Rev date: 12/02/02

Loxapina [Inn-Spanish] interactions

See also:
What other drugs will affect Loxapina [Inn-Spanish]?


There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) and lorazepam.

The risk of using Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) in combination with CNS-active drugs has not been systematically evaluated. Therefore, caution is advised if the concomitant administration of Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) and CNS-active drugs is required.

Loxapina [Inn-Spanish] side effects

See also:
What are the possible side effects of Loxapina [Inn-Spanish]?

CNS Effects: Manifestations of adverse effects on the central nervous system, other than extrapyramidal effects, have been seen infrequently. Drowsiness, usually mild, may occur at the beginning of therapy or when dosage is increased. It usually subsides with continued Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) therapy. The incidence of sedation has been less than that of certain aliphatic phenothiazines and slightly more than the piperazine phenothiazines. Dizziness, faintness, staggering gait, shuffling gait, muscle twitching, weakness, insomnia, agitation, tension, seizures, akinesia, slurred speech, numbness, and confusional states have been reported. Neuroleptic malignant syndrome (NMS) has been reported.

Extrapyramidal Symptoms - Neuromuscular (extrapyramidal) reactions during the administration of Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) have been reported frequently, often during the first few days of treatment. In most patients, these reactions involved parkinsonian-like symptoms such as tremor, rigidity, excessive salivation, and masked facies. Akathisia (motor restlessness) also has been reported relatively frequently. These symptoms are usually not severe and can be controlled by reduction of Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) dosage or by administration of antiparkinson drugs in usual dosage.

DystoniaClass effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

Persistent Tardive Dyskinesia- As with all antipsychotic agents, tardive dyskinesia may appear in some patients on long-term therapy or may appear after drug therapy has been discontinued. The risk appears to be greater in elderly patients on high-dose therapy, especially females. The symptoms are persistent and in some patients appear to be irreversible. The syndrome is characterized by rhythmical involuntary movement of the tongue, face, mouth or jaw (e.g., protrusion of tongue, puffing of cheeks, puckering of mouth, chewing movements). Sometimes these may be accompanied by involuntary movements of extremities.

There is no known effective treatment for tardive dyskinesia; antiparkinson agents usually do not alleviate the symptoms of this syndrome. It is suggested that all antipsychotic agents be discontinued if these symptoms appear. Should it be necessary to reinstitute treatment, or increase the dosage of the agent, or switch to a different antipsychotic agent, the syndrome may be masked. It has been suggested that fine vermicular movements of the tongue may be an early sign of the syndrome, and if the medication is stopped at that time the syndrome may not develop.

Cardiovascular Effects: Tachycardia, hypotension, hypertension, orthostatic hypotension, lightheadedness, and syncope have been reported.

A few cases of ECG changes similar to those seen with phenothiazines have been reported. It is not known whether these were related to Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) administration.

Hematologic: Rarely, agranulocytosis, thrombocytopenia, leukopenia.

Skin: Dermatitis, edema (puffiness of face), pruritus, rash, alopecia, and seborrhea have been reported with Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate).

Anticholinergic Effects: Dry mouth, nasal congestion, constipation, blurred vision, urinary retention, and paralytic ileus have occurred.

Gastrointestinal: Nausea and vomiting have been reported in some patients. Hepatocellular injury (i.e., SGOT/SGPT elevation) has been reported in association with Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) administration and rarely, jaundice and/or hepatitis questionably related to Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] (Loxapina [Inn-Spanish] succinate) succinate) succinate) treatment.

Other Adverse Reactions: Weight gain, weight loss, dyspnea, ptosis, hyperpyrexia, flushed facies, headache, paresthesia, and polydipsia have been reported in some patients. Rarely, galactorrhea, amenorrhea, gynecomastia, and menstrual irregularity of uncertain etiology have been reported.

Loxapina [Inn-Spanish] contraindications

See also:
What is the most important information I should know about Loxapina [Inn-Spanish]?


Loxapina [Inn-Spanish] is not for use in psychotic conditions related to dementia. Loxapina [Inn-Spanish] may cause heart failure, sudden death, or pneumonia in older adults with dementia-related conditions.

You should not use this medication if you are allergic to Loxapina [Inn-Spanish], or if you have decreased alertness caused by taking certain medications or drinking alcohol.

Call your doctor at once if you have restless muscle movements in your eyes, tongue, jaw, or neck.

Loxapina [Inn-Spanish] may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert.

Avoid drinking alcohol. You should not take Loxapina [Inn-Spanish] if you are under the effects of alcohol.

Avoid becoming overheated or dehydrated during exercise and in hot weather. Loxapina [Inn-Spanish] can decrease perspiration and you may be more prone to heat stroke.

Active ingredient matches for Loxapina [Inn-Spanish]:


List of Loxapina [Inn-Spanish] substitutes (brand and generic names)

Sort by popularity
Unit description / dosage (Manufacturer)Price, USD
Loxapax NA Syrup (D D Pharmaceuticals)$ 4.20
Capsule; Oral; Loxapine Succinate 10 mg
Capsule; Oral; Loxapine Succinate 25 mg
Capsule; Oral; Loxapine Succinate 5 mg
Capsule; Oral; Loxapine Succinate 50 mg
Tablet; Oral; Loxapine Succinate 10 mg
Tablet; Oral; Loxapine Succinate 25 mg
Tablet; Oral; Loxapine Succinate 5 mg
Tablet; Oral; Loxapine Succinate 50 mg
Loxapac 50 mg/ml$ 7.05
Loxitane 50 mg capsule$ 4.04
Loxitane 25 mg capsule$ 3.09
Loxapine 50 mg capsule$ 2.57
Loxitane 10 mg capsule$ 2.04
Loxapine 25 mg capsule$ 1.92
Loxitane 5 mg capsule$ 1.58
Loxapine 10 mg capsule$ 1.27
Loxapine Succinate 5 mg capsule$ 1.03
Loxapine 5 mg capsule$ 0.99
Pms-Loxapine 50 mg Tablet$ 0.54
Pms-Loxapine 25 mg Tablet$ 0.41
Pms-Loxapine 10 mg Tablet$ 0.26
Pms-Loxapine 5 mg Tablet$ 0.16
Pms-Loxapine 2.5 mg Tablet$ 0.08
Loxapine capsule 50 mg/1 (Lannett Company, Inc. (US))
Loxapine capsule 5 mg/1 (Carilion Materials Management (US))
Loxapine capsule 10 mg/1 (Mylan Institutional Inc. (US))
Loxapine tablet 50 mg/1 (Marlex Pharmaceuticals Inc (US))
Loxapine capsule 25 mg/1 (Mylan Institutional Inc. (US))
Loxapine tablet 5 mg/1 (Marlex Pharmaceuticals Inc (US))
Loxapine tablet 10 mg/1 (Marlex Pharmaceuticals Inc (US))
Loxapine tablet 25 mg/1 (Marlex Pharmaceuticals Inc (US))
10 mg x 100's (Sunrise)$ 10.95


  1. DailyMed. "LOXAPINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. PubChem. "loxapine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  3. DrugBank. "loxapine". http://www.drugbank.ca/drugs/DB00408 (accessed September 17, 2018).


The results of a survey conducted on ndrugs.com for Loxapina [Inn-Spanish] are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Loxapina [Inn-Spanish]. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet

Consumer reported price estimates

No survey data has been collected yet

Consumer reported time for results

No survey data has been collected yet

Consumer reported age

No survey data has been collected yet

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name: 
Spam protection:  < Type 27 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2019 ndrugs.com All Rights Reserved